



I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: October 20, 2003

Signature: Mark H. Hopkins

(Mark H. Hopkins, Ph.D.)

Docket No.: 28053/37955A
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Ian L. Brown, et al.

Application No.: 10/619,794

Filed: July 15, 2003

Art Unit: Not Yet Assigned

For: STARCH SUBTYPES AND LIPID
METABOLISM

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed within three months of the U.S. filing date (37 CFR 1.97(b)(1)). Those patents and publications which are marked with an asterisk (*) next to the Cite No. in the attached form PTO 1449 are not supplied because they were previously cited by or submitted to the Office in a prior application number 10/009,023, filed April 12, 2002 and relied upon in this application for an earlier filing date under 35 U.S.C. 120.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an

admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 13-2855. A duplicate copy of this paper is enclosed.

Dated: October 20, 2003

Respectfully submitted,

By MAH
Mark H. Hopkins, Ph.D.

Registration No.: 44,775
MARSHALL, GERSTEIN & BORUN LLP
233 S. Wacker Drive, Suite 6300
Sears Tower
Chicago, Illinois 60606-6357
(312) 474-6300
Agent for Applicants

Form PTO-1449 (Modified)	Atty. Docket No. 28053/37955A	Serial No. 10/619,794
	Applicant(s) Ian L. Brown, et al.	
	Filing Date July 15, 2003	Art Unit Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT**U.S. PATENT DOCUMENTS**

Examiner Initials	Document Number	Issue or Publication Date	Name	Class	Subclass	Filing Date (If Appropriate)

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Document Number	Publication Number	Publication Date	Country	Translation	
					Yes	No
	*B1	EP 0 506 166	09-30-1992	EPO		
	*B2	EP 0 550 060	07-07-1993	EPO		
	*B3	EP 0 747 397	12-11-1996	EPO		
	*B4	EP 0 846 704	06-10-1998	EPO		
	B5	WO94/03049	02-17-1994	PCT		
	B6	WO94/14342	07-07-1994	PCT		
	*B7	WO97/35889	10-02-1997	PCT		

OTHER DOCUMENTS

	*C1	Asp, N.G. "Resistant Starch-An Update on Its Physiological Effects," <i>Advances in Experimental Medicine and Biology</i> 427: 201-210 (1997).
	C2	Brown et al., "Hi-maize™: New directions in starch technology and nutrition," <i>Food Australia</i> 47: 272-275 (1995).
	*C3	International Search Report in PCT/AU01/00392, July 5, 2001.
	*C4	Kris-Etherton, P.M., "Is There an Optimal Diet for the Hypertriglyceridemic Patient?" <i>Journal of Cardiovascular Risk</i> 7(5): 333-337 (2000).
	C5	Storlien et al., "Syndromes of Insulin Resistance in the Rat: Inducement by Diet and Amelioration with Benfluorex," <i>Diabetes</i> 42: 457-462 (1993).
	C6	Xin et al., "Hypothalamic c-fos-like immunoreactivity in high-fat diet-induced obese and resistant mice," <i>Brain Research Bulletin</i> 52(4): 235-242 (2000).

EXAMINER:

DATE CONSIDERED: